Priortech Follow-Up: Camtek Value, Bond Collateral, and What Actually Reaches the Parent
Camtek's market value far exceeds Priortech's debt and cash, but 2025 shows that the liquidity cushion was built mainly through Series B issuance rather than upstream cash from holdings. As long as Camtek's value is filtered through pledged shares, LTV tests, and distribution restrictions, the gap between paper value and parent-level cash remains the real bottleneck.
The Asset Value Is Clear, the Cash Route Still Isn't
The main article argued that Priortech's issue is not asset scarcity but value access. This follow-up isolates the mechanism behind that gap: it is not enough that Camtek is worth a great deal, the real question is how much of that value is free, how much is already captured by bond collateral, and how much still sits one or two layers below the parent.
That is the whole point here. At the end of 2025 Priortech's Camtek stake carried a market value of about $1.023 billion, against a carrying value of only $164.4 million. That is a very large asset. But cash and cash equivalents stood at just $27.8 million, and in 2025 the company received no dividend from an associate, versus $12.1 million in 2024. The year in which paper value expanded was also a year in which cash did not move upstream from holdings, and the cushion was built mainly through the bond market.
So the right question is not whether Camtek has value. It plainly does. The right question is who gets first claim on that value on its way up: Series B bondholders, the LTV tests, the pledged-share account, or Priortech shareholders. As long as the answer starts with collateral and only ends with distributable cash, the parent may sit next to a strong asset while still behaving like a holding company with a narrow cash pipe.
In 2025 the Cash Cushion Came Mainly from New Debt, Not from Upstream Distributions
At year-end the company held $27.8 million of cash and cash equivalents, $11.1 million of short-term deposits, and another $6.3 million of trust cash and deposits. That is a much better liquidity picture than at the end of 2024, but the source matters more than the headline.
The cash flow statement sharpens the point. In 2025 Priortech posted negative operating cash flow of $3.5 million and negative investing cash flow of $15.1 million, against positive financing cash flow of $43.4 million. That is not the profile of a year in which value moved up the chain. It is the profile of a year in which the company refinanced itself, replaced Series A with Series B, and rebuilt liquidity through capital markets.
The comparison with 2024 is even more telling. In 2024 Priortech received a $12.1 million dividend from an associate. In 2025 that line fell to zero. Anyone looking only at the year-end cash balance can miss the economic structure behind it: the cash is there, but it rests mainly on issuance and series expansion, not on recurring upstream cash from Camtek or Access.
The board's own financing discussion leads to the same conclusion. The increase in cash came mainly from Series B proceeds, offset by current expenses and the repayment of Series A principal and interest totaling about NIS 151.5 million. This matters because the 2025 cushion was not created by recurring cash generation at the parent. It was rebuilt through funding.
The Holding Value Is Large, but Not Every Value Layer Is Available Cash
The note on investees shows how extreme the gap is between holding value and accessible liquidity at Priortech.
| Layer | 31.12.2025 | What it means in practice |
|---|---|---|
| Camtek stake market value | $1,022.9 million | A very large asset, but not cash at the parent |
| Camtek carrying value | $164.4 million | The accounting value, not the free monetizable value |
| Capital notes funded into Amitek | $103.1 million | Value sitting below the parent, not automatically coming back up |
| Series B bonds on balance sheet | $93.3 million | Parent-level debt already sitting against that value layer |
| Cash and cash equivalents | $27.8 million | This is the truly liquid layer |
This is the real warning flag. On the one hand, Camtek alone is worth far more than Priortech's debt stack. On the other hand, the Amitek capital notes are a reminder that not all group value already sits at the top. The investment agreement says that most of PC's investment in Amitek, $24 million out of $25 million, was provided as non-interest-bearing capital notes. Priortech funded Amitek in a similar form. Those notes have no interest rate, no maturity date, and repayment depends on one of three events: a dividend from Access, a sale of Amitek's Access stake, or an Amitek board decision.
That is where the holdco lens becomes essential. A capital note into Amitek is not cash at Priortech, and it is not a scheduled receivable that naturally moves toward the parent. It is event-driven value. So even if Access keeps generating profits and even if Camtek keeps expanding Priortech's asset value, it does not automatically follow that cash will move up at the pace parent shareholders would want.
Series B Collateral Is the Real Gatekeeper
Series B is not unsecured holdco debt quietly waiting for 2030. It is tied directly to Priortech's core asset. As of the report date, the company had pledged 1.45 million Camtek shares in a first-ranking fixed pledge for the benefit of Series B bondholders. The collateral package goes beyond the shares themselves. It also captures the related rights, including cash or in-kind dividends, other distributions, rights to other securities, compensation rights, sale proceeds, and the rights in the pledged-share account.
That means the bondholders do not only sit against the stock. They also sit against what comes out of the stock. Anyone reading Camtek as if it were an open cash drawer for Priortech is missing the seniority built into the collateral structure.
| Test | Threshold | Actual | Why it matters |
|---|---|---|---|
| LTV | must not exceed 60% | 55.3% at 31.12.2025 | This is the live constraint |
| Post-distribution LTV | must not exceed 58% | 55.3% before any payout | Only 2.7 percentage points of year-end headroom |
| Release of pledged shares | available only below 50% LTV | 42.3% at 20.03.2026 | The real cushion only opened after year-end |
| Equity | at least $100 million for two consecutive quarters | $262 million | Wide headroom |
| Equity-to-assets | at least 31% for two consecutive quarters | 66.3% | Also comfortably clear |
The table makes the hierarchy clear. Equity and equity-to-assets are nowhere near their limits. The live bottleneck is LTV. At year-end the company was compliant, but not with a huge margin. If it wanted to distribute cash to shareholders, it had to remain below 58% even after the distribution. On year-end numbers, that is not much room.
The more interesting feature is that the indenture works in both directions. If LTV rises above 60%, the company must pledge additional Camtek shares within 14 days. If LTV falls below 50%, it may request the release of some pledged shares. In other words, a rising Camtek share price can open room, but a falling one can trap more of the stake inside the bond package. That turns Camtek stock into more than an asset. It becomes the mechanism that widens or narrows Priortech's cash pipe.
There is another layer. The Series B distribution restrictions require not only compliance with LTV, but also minimum equity, minimum equity-to-assets, and the absence of warning signs. In the 2025 report the company explicitly states that, as of 31 December 2025, it had a warning sign under the regulations because of continuing negative operating cash flow. The board says this does not indicate a liquidity problem. That may be true. But from a capital-allocation perspective the implication is clear: even when the asset above is strong, the ability to move value below remains constrained by more than Camtek's share price.
What Changes the Read from Here
As of 20 March 2026 the LTV ratio had already fallen to 42.3%. That is a meaningfully better picture than the 55.3% seen at year-end. It suggests that immediate pressure on the 60% line eased materially and, in principle, even opens the door to releasing some pledged shares. But it still does not solve the central question of this follow-up: does Camtek value actually arrive at Priortech as cash, or does it merely improve collateral headroom.
The latest market snapshot points in the same direction. As of 3 April 2026 Priortech's market cap stood at about NIS 3.16 billion, while the Series B bond market value stood at about NIS 306.7 million. The obvious reading is that the market still looks first through the asset lens. This continuation argues that investors should watch the route as closely as the destination: a real Camtek dividend, a sale event, a cash distribution from Access, or a sustained easing of the collateral constraint matter more than one more step-up in paper value.
That is why Priortech still reads like a holdco where the value is much clearer than the accessibility of the value. In 2025 cash did not move upstream from holdings. It came mainly from the new bond. Camtek gives the company a strong collateral base and some flexibility as long as the share price supports it, but that same stock is also the first asset to be locked more tightly if LTV becomes stressed. And Amitek is a reminder that another value layer still sits below the parent in the form of event-driven capital notes.
The thesis now: Priortech is not a story of insufficient assets. It is a story of claim priority over those assets. As long as cash reaching the top depends more on refinancing, collateral mechanics, and LTV tests than on dividends and realizations, a practical discount to paper value remains justified even when Camtek itself keeps delivering good news.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.